Physician profile
Eman Albaddawi
NPI 1730490053
$5,919.66
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $488 · 2021: $418 · 2022: $1,422 · 2023: $2,295 · 2024: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,047.63 |
| Education | $250.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,160.90 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $715.15 | 2019-2024 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.55 | 2020-2024 | Ofev |
| Regeneron Healthcare Solutions, INC. | $694.36 | 2019-2024 | Dupixent |
| United Therapeutics Corporation | $324.99 | 2022-2024 | Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $297.49 | 2022-2023 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $249.30 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $202.99 | 2019-2023 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $172.04 | 2022-2024 | Glassia, Hyqvia |
| Philips North America LLC | $138.60 | 2022 | |
| Astellas Pharma US INC | $134.90 | 2023 | Cresemba, Ambisome |
| Electromed, INC. | $125.83 | 2019-2024 | Smartvest |
| Baxter Healthcare | $120.53 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $120.05 | 2019-2023 | |
| Amgen INC. | $114.95 | 2023-2024 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $95.39 | 2021-2022 | |
| Genentech USA, INC. | $93.15 | 2019-2021 | |
| Pfizer INC. | $90.37 | 2019-2023 | |
| Advanced Respiratory, INC | $59.54 | 2021 | |
| Covis Pharma Gmbh | $44.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36.17 | 2022-2023 | Airduo Digihaler |
| Bayer Healthcare Pharmaceuticals INC. | $34.52 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.27 | 2024 | |
| Merck Sharp & Dohme LLC | $31.16 | 2023-2024 | Winrevair |
| Csl Behring | $29.79 | 2023 | Hizentra |
| Lilly USA, LLC | $19.53 | 2024 | Mounjaro |
| Insmed, INC. | $18.72 | 2024 | Arikayce |
| Otsuka America Pharmaceutical, INC. | $18.08 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $15.43 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $15.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Albaddawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.